INT25988

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1989
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 2.68
Pain Relevance 1.68

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Pla2g5) Golgi apparatus (Pla2g5) plasma membrane (Pla2g5)
Anatomy Link Frequency
neurons 1
Pla2g5 (Mus musculus)
Pain Link Frequency Relevance Heat
Kinase C 10 100.00 Very High Very High Very High
tetrodotoxin 4 99.32 Very High Very High Very High
Inflammation 29 99.16 Very High Very High Very High
Inflammatory response 6 99.08 Very High Very High Very High
agonist 32 87.20 High High
antagonist 37 85.92 High High
cerebral cortex 5 82.32 Quite High
ischemia 39 80.32 Quite High
nociceptor 46 62.36 Quite High
qutenza 23 57.20 Quite High
Disease Link Frequency Relevance Heat
Injury 27 99.20 Very High Very High Very High
INFLAMMATION 31 99.16 Very High Very High Very High
Nociception 17 98.88 Very High Very High Very High
Middle Cerebral Artery Infarction 37 97.32 Very High Very High Very High
Pressure And Volume Under Development 7 96.08 Very High Very High Very High
Disease 19 90.56 High High
Stroke 7 85.60 High High
Cv Unclassified Under Development 32 80.32 Quite High
Stress 11 55.32 Quite High
Pain 96 50.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These results demonstrate that surfactin is a selective inhibitor for cytosolic PLA2 and a putative anti-inflammatory agent through the inhibitory effect produced by direct interaction with cytosolic PLA2, and that inhibition of cytosolic PLA2 activity may suppress inflammatory responses.
Negative_regulation (inhibition) of PLA2 associated with inflammatory response and inflammation
1) Confidence 0.58 Published 1998 Journal Biochem. Pharmacol. Section Abstract Doc Link 9605421 Disease Relevance 0.70 Pain Relevance 0.26
Mepacrine, an inhibitor of phospholipase A2 (PLA2) activity and hence of arachidonic acid (AA) formation from membrane phospholipids, markedly inhibits (IC50 of approximately 15 microM) the release of VIP evoked by 4-AP.
Negative_regulation (inhibitor) of PLA2
2) Confidence 0.54 Published 1989 Journal J. Neurosci. Section Abstract Doc Link 2545840 Disease Relevance 0 Pain Relevance 0.43
Indeed, Miettinen and co-authors used a nonspecific PLA2 inhibitor to ameliorate both injury and COX-2 induction following transient MCAO and suggested that neurons that express cPLA2?
Negative_regulation (inhibitor) of PLA2 in neurons associated with middle cerebral artery infarction and injury
3) Confidence 0.46 Published 2010 Journal J Neuroinflammation Section Body Doc Link PMC2923122 Disease Relevance 0.96 Pain Relevance 0.04
These results demonstrate that surfactin is a selective inhibitor for cytosolic PLA2 and a putative anti-inflammatory agent through the inhibitory effect produced by direct interaction with cytosolic PLA2, and that inhibition of cytosolic PLA2 activity may suppress inflammatory responses.
Negative_regulation (inhibitor) of PLA2 associated with inflammatory response and inflammation
4) Confidence 0.43 Published 1998 Journal Biochem. Pharmacol. Section Abstract Doc Link 9605421 Disease Relevance 0.72 Pain Relevance 0.27
Inhibition of PLC, PKC, PLA2, and PKA reduce peripheral nociception [61, 79].
Negative_regulation (Inhibition) of PLA2 associated with nociception and kinase c
5) Confidence 0.10 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2645548 Disease Relevance 0.29 Pain Relevance 0.67

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox